デフォルト表紙
市場調査レポート
商品コード
1451625

バイオマーカー市場レポート:製品タイプ、疾患、用途、エンドユーザー、地域別、2024-2032

Biomarkers Market Report by Product, Type, Disease, Application, End User, and Region 2024-2032

出版日: | 発行: IMARC | ページ情報: 英文 140 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
バイオマーカー市場レポート:製品タイプ、疾患、用途、エンドユーザー、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

バイオマーカーの世界市場規模は2023年に799億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて11.37%の成長率(CAGR)を示し、2032年までに2,207億米ドルに達すると予測しています。慢性疾患の増加、バイオテクノロジーとゲノミクスの継続的な発展、個別化医療へのシフト、分析技術の継続的な進歩、バイオマーカーの利点に関するヘルスケア専門家と患者の両方の意識の高まりは、市場を推進する主な要因のいくつかです。

バイオマーカーは人体内で測定可能な指標であり、様々な生物学的プロセスや状態に関する重要な情報を提供します。バイオマーカーには、タンパク質、遺伝子、ホルモン、あるいは身体的特徴など、さまざまな物質が含まれます。バイオマーカーは医学研究、診断、治療計画において重要な役割を果たしています。バイオマーカーによって、ヘルスケア専門家や研究者は、病気の有無や進行を評価したり、治療の効果をモニターしたり、特定の健康問題に対する個人の感受性を予測したりすることができます。市場調査やコンサルティングサービスの領域では、バイオマーカーの理解は極めて重要であり、ヘルスケアや製薬業界の意思決定プロセスを導き、革新的なソリューションや戦略の開発に役立っています。

がん、心血管疾患、糖尿病などの慢性疾患の増加は、世界全体の市場成長を促進する重要な要因の一つです。早期発見、疾患モニタリング、個別化治療戦略の開発に不可欠です。バイオテクノロジーとゲノミクスの継続的な進歩により、新規バイオマーカーの発見が進み、診断、医薬品開発、精密医療への応用が拡大しています。バイオマーカーは、標的同定、薬剤候補の有効性評価、安全性プロファイリングに役立ち、製薬研究にとって不可欠です。これによって医薬品開発が加速し、コストが削減され、成功率が高まる。個別化医療へのシフトは、個々の患者のプロファイルに合わせて治療計画を調整し、治療成績を向上させ、副作用を最小限に抑えるために、バイオマーカーに大きく依存しています。高齢者は慢性疾患にかかりやすいため、バイオマーカーによる早期発見と効果的な管理が必要となります。ゲノミクス、プロテオミクス、イメージングなどの分析技術の絶え間ない改善により、バイオマーカー検出の感度と特異性が向上し、その応用範囲が広がっているため、バイオマーカー市場の成長は世界中で促進されています。

バイオマーカー市場の動向と促進要因:

疾病負担とヘルスケアコストの増加

バイオマーカー市場の主な促進要因の1つは、世界の疾病負担の増大であり、特にがん、心血管疾患、糖尿病などの慢性疾患が顕著です。バイオマーカーはこれらの疾患の早期発見、診断、モニタリングにおいて極めて重要な役割を果たしています。バイオマーカーによって、ヘルスケア専門家は病気のリスクを特定し、治療戦略を立て、治療反応をより効果的に追跡することができます。ヘルスケアシステムが、増加する疾病負担を管理するという課題に直面する中、バイオマーカーは、早期介入や標的治療を通じて患者の転帰を改善し、医療費を削減するための貴重なツールとなります。

バイオテクノロジーと個別化医療の著しい進歩

ゲノミクス、プロテオミクス、ハイスループットスクリーニングを含むバイオテクノロジーツールや技術の絶え間ない進歩は、バイオマーカーの発見と検証に革命をもたらしました。その結果、高い特異性と感度を持つ新規バイオマーカーが同定され、診断と予後の能力が向上しました。さらに、個別化医療へのパラダイムシフトは、個々の患者のプロファイルに合わせた治療を行うためのバイオマーカーに大きく依存しています。バイオマーカー主導のアプローチにより、ヘルスケアプロバイダーは最適な治療法を選択することが可能となり、治療効果を高め、副作用を最小限に抑えることができます。これにより、患者の治療が改善されるだけでなく、バイオマーカーに基づく検査や治療に対する需要も高まっています。

医薬品開発と臨床試験の増加

バイオマーカーは製薬業界において不可欠なものとなりつつあり、創薬と薬剤開発を促進しています。バイオマーカーは、標的の同定、臨床試験における患者の層別化、薬剤の有効性と安全性の評価を容易にします。その結果、医薬品開発プロセスが合理化され、コストが削減され、新薬の上市成功率が高まる。FDAやEMAなどの規制機関は、医薬品承認におけるバイオマーカーの重要性をますます認識するようになっており、臨床試験や医薬品開発パイプラインへのバイオマーカーの統合をさらに加速させています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 バイオマーカーの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳:製品別

  • 消耗品
    • 市場動向
    • 市場予測
  • サービス
    • 市場動向
    • 市場予測
  • ソフトウェア
    • 市場動向
    • 市場予測

第7章 市場内訳:タイプ別

  • 有効性バイオマーカー
    • 市場動向
    • 市場予測
  • 安全性バイオマーカー
    • 市場動向
    • 市場予測
  • バリデーションバイオマーカー
    • 市場動向
    • 市場予測

第8章 市場内訳:疾患別

  • がん
    • 市場動向
    • 市場予測
  • 心血管疾患
    • 市場動向
    • 市場予測
  • 神経疾患
    • 市場動向
    • 市場予測
  • 免疫疾患
    • 市場動向
    • 市場予測
  • 腎疾患
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳:アプリケーション別

  • 診断薬
    • 市場動向
    • 市場予測
  • 創薬・医薬品開発
    • 市場動向
    • 市場予測
  • 個別化医療
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳:エンドユーザー別

  • 製薬・バイオ企業
    • 市場動向
    • 市場予測
  • 診断・研究機関
    • 市場動向
    • 市場予測
  • 病院と専門クリニック
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第11章 市場内訳:地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳:国別
    • 市場予測

第12章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格分析

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories Inc.
    • Charles River Laboratories International Inc.
    • Epigenomics AG
    • Eurofins Scientific SE
    • Merck KGaA
    • Perkinelmer Inc.
    • Qiagen N.V
    • Quanterix Corporation
    • SphingoTec GmbH
    • Thermo Fisher Scientific Inc.
図表

List of Figures

  • Figure 1: Global: Biomarkers Market: Major Drivers and Challenges
  • Figure 2: Global: Biomarkers Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Biomarkers Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Biomarkers Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Biomarkers Market: Breakup by Type (in %), 2023
  • Figure 6: Global: Biomarkers Market: Breakup by Disease (in %), 2023
  • Figure 7: Global: Biomarkers Market: Breakup by Application (in %), 2023
  • Figure 8: Global: Biomarkers Market: Breakup by End User (in %), 2023
  • Figure 9: Global: Biomarkers Market: Breakup by Region (in %), 2023
  • Figure 10: Global: Biomarkers (Consumables) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Biomarkers (Consumables) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Biomarkers (Services) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Biomarkers (Services) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Biomarkers (Software) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Biomarkers (Software) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Biomarkers (Efficacy Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Biomarkers (Efficacy Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Biomarkers (Safety Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Biomarkers (Safety Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Biomarkers (Validation Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Biomarkers (Validation Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Biomarkers (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Biomarkers (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Biomarkers (Cardiovascular Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Biomarkers (Cardiovascular Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Biomarkers (Neurological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Biomarkers (Neurological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Biomarkers (Immunological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Biomarkers (Immunological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Biomarkers (Renal Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Biomarkers (Renal Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Biomarkers (Other Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Biomarkers (Other Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Biomarkers (Diagnostics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Biomarkers (Diagnostics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Biomarkers (Drug Discovery and Development) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Biomarkers (Drug Discovery and Development) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Biomarkers (Personalized Medicine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Biomarkers (Personalized Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Biomarkers (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: Biomarkers (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: Biomarkers (Pharmaceutical and Biotechnology Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: Biomarkers (Pharmaceutical and Biotechnology Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Global: Biomarkers (Diagnostic and Research Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Global: Biomarkers (Diagnostic and Research Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Global: Biomarkers (Hospitals and Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Global: Biomarkers (Hospitals and Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Global: Biomarkers (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Global: Biomarkers (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: North America: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: North America: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: United States: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: United States: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Canada: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Canada: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Asia-Pacific: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Asia-Pacific: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: China: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: China: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Japan: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Japan: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: India: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: India: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: South Korea: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: South Korea: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Australia: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Australia: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Indonesia: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Indonesia: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Europe: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Europe: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Germany: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Germany: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: France: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: France: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: United Kingdom: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: United Kingdom: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Italy: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Italy: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Spain: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Spain: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Russia: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Russia: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Others: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Others: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Latin America: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Latin America: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Brazil: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Brazil: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Mexico: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 93: Mexico: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 94: Others: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 95: Others: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Middle East and Africa: Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 97: Middle East and Africa: Biomarkers Market: Breakup by Country (in %), 2023
  • Figure 98: Middle East and Africa: Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 99: Global: Biomarkers Industry: SWOT Analysis
  • Figure 100: Global: Biomarkers Industry: Value Chain Analysis
  • Figure 101: Global: Biomarkers Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Biomarkers Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Biomarkers Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Biomarkers Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 4: Global: Biomarkers Market Forecast: Breakup by Disease (in Million US$), 2024-2032
  • Table 5: Global: Biomarkers Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 6: Global: Biomarkers Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 7: Global: Biomarkers Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Biomarkers Market: Competitive Structure
  • Table 9: Global: Biomarkers Market: Key Players
目次
Product Code: SR112024A6320

The global biomarkers market size reached US$ 79.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 220.7 Billion by 2032, exhibiting a growth rate (CAGR) of 11.37% during 2024-2032. The rising prevalence of chronic diseases, ongoing developments in biotechnology and genomics, the shift toward personalized medicine, continuous advancements in analytical technologies, and increasing awareness among both healthcare professionals and patients about the benefits of biomarkers are some of the major factors propelling the market.

Biomarkers are measurable indicators within the human body that provide essential information about various biological processes and conditions. These markers can encompass a wide range of substances, including proteins, genes, hormones, or even physical characteristics. Biomarkers play a crucial role in medical research, diagnosis, and treatment planning. They enable healthcare professionals and researchers to assess the presence or progression of diseases, monitor the effectiveness of therapies, and predict an individual's susceptibility to certain health issues. In the realm of market research and consulting services, understanding biomarkers is pivotal, as they guide decision-making processes in healthcare and pharmaceutical industries, aiding in the development of innovative solutions and strategies.

The rise in chronic diseases, including cancer, cardiovascular disorders, and diabetes, represents one of the key factors driving the growth of the market across the globe. They are indispensable for early detection, disease monitoring, and the development of personalized treatment strategies. The continuous progress in biotechnology and genomics is leading to the discovery of novel biomarkers, expanding their applications across diagnostics, drug development, and precision medicine. Biomarkers are integral to pharmaceutical research, assisting in target identification, drug candidate efficacy evaluation, and safety profiling. This accelerates drug development, reduces costs, and enhances success rates. The shift towards personalized medicine relies heavily on biomarkers to tailor treatment plans to individual patient profiles, improving treatment outcomes and minimizing side effects. The globally aging population is a key driver, as elderly individuals are more prone to chronic diseases, necessitating early detection and effective management using biomarkers. Continuous improvements in analytical technologies, such as genomics, proteomics, and imaging enhance the sensitivity and specificity of biomarker detection, which is broadening their applications, thus facilitating the market growth across the globe.

Biomarkers Market Trends/Drivers:

Rising disease burden and healthcare costs

One of the primary drivers of the biomarkers market is the escalating global burden of diseases, particularly chronic conditions like cancer, cardiovascular diseases, and diabetes. Biomarkers play a pivotal role in the early detection, diagnosis, and monitoring of these diseases. They enable healthcare professionals to identify disease risks, formulate treatment strategies, and track treatment responses more effectively. As healthcare systems face the challenge of managing these increasing disease burdens, biomarkers provide a valuable tool for improving patient outcomes and reducing healthcare costs through early intervention and targeted therapies.

Significant advancements in biotechnology and personalized medicine

The continuous advancement of biotechnological tools and techniques, including genomics, proteomics, and high-throughput screening, has revolutionized biomarker discovery and validation. This has led to the identification of novel biomarkers with high specificity and sensitivity, enhancing their diagnostic and prognostic capabilities. Moreover, the paradigm shift towards personalized medicine relies heavily on biomarkers to tailor treatments to individual patient profiles. Biomarker-driven approaches enable healthcare providers to select the most suitable therapies, thereby increasing treatment efficacy and minimizing adverse effects. This has not only improved patient care but has also intensified the demand for biomarker-based tests and therapies.

Rise in drug development and clinical trials

Biomarkers are becoming indispensable in the pharmaceutical industry, which is driving drug discovery and development, thus acting as a major growth-inducing factor. They facilitate target identification, patient stratification for clinical trials, and assessment of drug efficacy and safety. This results in streamlined drug development processes, reduced costs, and increased success rates in bringing new drugs to market. Regulatory agencies, such as the FDA and EMA, increasingly recognize the significance of biomarkers in drug approvals, which is further accelerating their integration into clinical trials and drug development pipelines.

Biomarkers Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global biomarkers market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, type, disease, application, and end user.

Breakup by Product:

Consumables

Services

Software

Consumables dominate the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes consumables, services, and software. According to the report, consumables represented the largest segment.

The demand for consumables in the biomarkers market is driven by several influential factors. Primarily, the continuous expansion of biomarker research in various fields, including oncology, cardiology, and neuroscience, necessitates a steady supply of consumables. Researchers rely on consumables such as assay kits, reagents, and laboratory supplies to conduct experiments and validate biomarkers for clinical applications. The growing adoption of biomarkers for clinical diagnostics fuels demand for consumables used in diagnostic tests. Consumables like test kits, sample collection devices, and assay reagents are essential for accurate biomarker-based diagnosis, enabling early disease detection and monitoring. Biomarkers are integral to drug discovery and development, where consumables like cell culture media, plates, and assay components are essential. The pharmaceutical industry's robust pipeline of biomarker-driven therapies and the need for large-scale screening drive demand for consumables. The trend towards personalized medicine, which relies on biomarkers for treatment tailoring, has increased the need for consumables. Customized therapies based on individual biomarker profiles require specific consumables for their development and administration.

Breakup by Type:

Efficacy Biomarkers

Safety Biomarkers

Validation Biomarkers

Safety biomarkers hold the largest share in the market

The report has provided a detailed breakup and analysis of the market based on the type. This includes efficacy biomarkers, safety biomarkers, and validation biomarkers. According to the report, safety biomarkers represented the largest segment.

The demand for safety biomarkers in the biomarkers industry is influenced by several critical factors. Regulatory agencies, such as the FDA and EMA, mandate the evaluation of safety biomarkers in drug development to assess potential adverse effects and toxicity. Compliance with these regulations drives the demand for safety biomarker assays and testing services. The high costs associated with drug development, including the expenses incurred due to adverse events and late-stage failures, underscore the importance of safety biomarkers. Early detection of safety concerns can significantly reduce development expenses, prompting the pharmaceutical industry to invest in safety biomarker research and implementation. Ensuring patient safety is paramount in clinical trials. The utilization of safety biomarkers helps identify and mitigate potential risks to participants, aligning with ethical and safety considerations. Technological advancements, such as omics technologies (genomics, proteomics, metabolomics), enable the discovery of novel safety biomarkers with enhanced sensitivity and specificity. The availability of cutting-edge tools and assays drives the adoption of safety biomarkers in drug safety assessment.

Breakup by Disease:

Cancer

Cardiovascular Disorders

Neurological Disorders

Immunological Disorders

Renal Disorders

Others

Cancer dominates the market

The report has provided a detailed breakup and analysis of the market based on the disease. This includes cancer, cardiovascular disorders, neurological disorders, immunological disorders, renal disorders, and others. According to the report, cancer represented the largest segment.

Biomarkers play a pivotal role in cancer research, diagnosis, treatment, and patient management. Their applications in cancer are multifaceted and essential. Primarily, biomarkers enable the early detection of cancer, often before symptoms manifest. Blood-based biomarkers, such as circulating tumor DNA (ctDNA) and specific proteins like PSA (Prostate-Specific Antigen), aid in screening and early diagnosis. Biomarkers help confirm cancer diagnoses and classify tumors into specific subtypes. For instance, hormone receptor status (estrogen and progesterone receptors) in breast cancer guides treatment decisions. Biomarkers provide prognostic information, helping predict the course of the disease. Genetic markers and gene expression profiles assist in estimating a patient's likely outcome and risk of recurrence. Biomarkers guide treatment decisions by identifying targeted therapies. For instance, the presence of HER2/neu in breast cancer indicates eligibility for HER2-targeted therapies like trastuzumab. Biomarkers are used to monitor treatment efficacy and disease progression. Imaging biomarkers, like PET scans, assess tumor response to therapy, aiding treatment adjustments.

Breakup by Application:

Diagnostics

Drug Discovery and Development

Personalized Medicine

Others

Drug discovery and development hold the largest share in the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes diagnostics, drug discovery and development, personalized medicine, and others. According to the report, drug discovery and development represented the largest segment.

Biomarkers are indispensable tools in drug discovery and development, offering several critical applications that streamline the process and increase its efficiency. Biomarkers help identify and validate potential drug targets by providing insights into their role in disease pathways. This ensures that drug development efforts are focused on biologically relevant targets. Biomarkers aid in assessing the effectiveness of drug candidates during preclinical and clinical trials. They provide quantifiable measurements of the drug's impact on the target and its downstream effects, helping to select the most promising candidates. Safety biomarkers are crucial for evaluating the potential adverse effects of drug candidates. They help identify safety concerns early in the development process, reducing the risk of late-stage failures. Biomarkers enable the stratification of patient populations, identifying subgroups that are more likely to respond to a specific treatment. This supports the development of targeted therapies, optimizing treatment outcomes.

Breakup by End User:

Pharmaceutical and Biotechnology Companies

Diagnostic and Research Laboratories

Hospitals and Specialty Clinics

Others

Diagnostic and research laboratories dominates the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes pharmaceutical and biotechnology companies, diagnostic and research laboratories, hospitals and specialty clinics, and others. According to the report, diagnostic and research laboratories represented the largest segment.

Biomarkers have a significant impact on the operations of diagnostic and research laboratories, serving a wide range of crucial purposes. Biomarkers are fundamental in clinical diagnostics, aiding in the accurate and early diagnosis of various diseases. They provide measurable indicators of disease presence or progression, enhancing diagnostic precision. Biomarkers enable the categorization of patients into different risk groups or disease subtypes, helping healthcare providers tailor treatment plans to individual profiles. In research and clinical settings, biomarkers are used to monitor disease progression and assess the effectiveness of treatments. This helps in disease management and optimization of therapeutic interventions. Laboratories use biomarkers to evaluate drug responses, assess drug metabolism, and understand the relationship between drug dose and effect. Biomarkers play a role in assessing the safety of drugs and therapies and identifying potential side effects and toxicities. Biomarkers serve as key tools in laboratory research, aiding in the discovery of new disease mechanisms, drug targets, and potential therapeutic interventions.

Breakup by Region:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Russia

Spain

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Russia, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The biomarkers industry in North America is driven by several influential factors that contribute to its growth and development. The high prevalence of chronic diseases, including cancer, cardiovascular disorders, and diabetes, in North America has fueled the demand for biomarkers. Biomarkers are crucial for early detection, monitoring, and treatment selection in these conditions. North America boasts a well-developed healthcare infrastructure, including state-of-the-art laboratories and research facilities. This infrastructure supports biomarker research, development, and implementation. The region is home to a robust biotechnology and pharmaceutical industry. Biomarkers play a central role in drug discovery, development, and clinical trials, driving their demand. Regulatory agencies like the FDA in the United States have recognized the importance of biomarkers in drug development and diagnostics. Clear regulatory pathways for biomarker-based products encourage their use. Significant investments in research and development (R&D), both public and private, support biomarker discovery and validation, enhancing their role in healthcare. Ongoing technological advancements in genomics, proteomics, and diagnostic technologies are improving the accuracy and efficiency of biomarker assays.

Competitive Landscape:

Key players in the market are actively engaged in various strategic initiatives to advance research, development, and commercialization in this dynamic field. Leading companies invest heavily in R&D to discover and validate novel biomarkers. They collaborate with academic institutions and research organizations to expand their biomarker portfolios. Many biomarker companies form strategic partnerships with pharmaceutical and biotechnology firms to integrate biomarkers into drug development pipelines. These collaborations aim to identify biomarkers for patient stratification and treatment response prediction. Companies continuously expand their biomarker product portfolios, offering a wide range of assays, kits, and services for diverse applications, from diagnostics to drug development. Leading players invest in cutting-edge technologies, such as next-generation sequencing and mass spectrometry, to enhance the sensitivity and specificity of biomarker detection methods. Some key players focus on developing companion diagnostics, and aligning biomarker tests with specific therapies to ensure precise treatment selection and improve patient outcomes.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Agilent Technologies Inc.

Bio-Rad Laboratories Inc.

Charles River Laboratories International Inc.

Epigenomics AG

Eurofins Scientific SE

Merck KGaA

Perkinelmer Inc.

Qiagen N.V

Quanterix Corporation

SphingoTec GmbH

Thermo Fisher Scientific Inc.

Recent Developments:

In June 2023, FDA announced a new voluntary pilot program for certain oncology drug products used with certain corresponding in-vitro diagnostic tests. The goal of this program is to help clinicians select appropriate cancer treatments for patients.

In March 2022, Union Health Minister Mansukh Madaviya launched the Diet and Biomarkers Survey in India (DABS-I) at the National Institute of Nutrition (NIN) here on Saturday.

November 30, 2020, Agilent announced launch of global biomarker pathologist training program, designed to enrich pathologists' skills in biomarker interpretation and scoring techniques.

Key Questions Answered in This Report

  • 1. What was the size of the global biomarkers market in 2023?
  • 2. What is the expected growth rate of the global biomarkers market during 2024-2032?
  • 3. What are the key factors driving the global biomarkers market?
  • 4. What has been the impact of COVID-19 on the global biomarkers market?
  • 5. What is the breakup of the global biomarkers market based on the product?
  • 6. What is the breakup of the global biomarkers market based on the type?
  • 7. What is the breakup of the global biomarkers market based on disease?
  • 8. What is the breakup of the global biomarkers market based on the application?
  • 9. What is the breakup of the global biomarkers market based on the end user?
  • 10. What are the key regions in the global biomarkers market?
  • 11. Who are the key players/companies in the global biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biomarkers Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Consumables
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Services
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Software
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Efficacy Biomarkers
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Safety Biomarkers
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Validation Biomarkers
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Disease

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cardiovascular Disorders
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Neurological Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Immunological Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Renal Disorders
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Diagnostics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Drug Discovery and Development
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Personalized Medicine
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Pharmaceutical and Biotechnology Companies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Diagnostic and Research Laboratories
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Hospitals and Specialty Clinics
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Agilent Technologies Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Bio-Rad Laboratories Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Charles River Laboratories International Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Epigenomics AG
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Eurofins Scientific SE
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Merck KGaA
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Perkinelmer Inc.
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Qiagen N.V
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Quanterix Corporation
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
    • 16.3.10 SphingoTec GmbH
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
    • 16.3.11 Thermo Fisher Scientific Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis